Gerresheimer’s packaging sale to Apax Partners is one of the largest packaging M&A deals of 2026, with the German company agreeing to offload its Centor and global Primary Packaging Plastics businesses for a combined enterprise value of €1.5 billion ($1.7 billion). The move, announced on July 29, 2026, marks a decisive step in Gerresheimer’s plan to shed lower-margin plastics operations and concentrate on high-value drug delivery systems and medical devices.
Under the agreement, an affiliate of funds advised by private equity firm Apax Partners will acquire Centor, a US-based unit that supplies packaging systems for dispensing prescription drugs, along with Gerresheimer’s global Primary Packaging Plastics business. The deal covers the Centor production site in the United States plus 15 manufacturing locations for primary plastic packaging spread across nine countries. Together, the two units generated roughly €570 million in revenue in 2025 and employ about 2,400 people worldwide. Gerresheimer, headquartered in Dusseldorf, said each transaction will proceed separately and remains subject to customary closing conditions and regulatory approvals.
Why Is Gerresheimer Selling Its Plastic Packaging Business?
Gerresheimer’s packaging sale is designed to raise cash and sharply reduce debt after a difficult financial year. The company reported a consolidated net loss of €318.7 million for fiscal 2025, compared with an adjusted net income of €84.3 million a year earlier, a swing driven largely by €521.5 million in non-cash depreciation, amortization and impairment charges. Chief financial officer Wolf Lehmann said the company will use the expected cash inflows to “accelerate our debt reduction,” adding that combined with a planned comprehensive refinancing, the move “will significantly reduce our interest expenses and achieve a sustainable capital structure.” CEO Uwe Rohrhoff said divesting Centor and the Primary Packaging Plastics unit lets the company sharpen its focus on “high-value” drug delivery systems, medical devices and primary packaging for injectable drugs, segments it considers core to future growth.
What Does the Deal Mean for the Broader Packaging Industry?
The transaction adds to a wave of portfolio restructuring among large pharmaceutical and healthcare packaging players in 2026, as manufacturers try to separate commodity plastics operations from specialized, higher-margin drug-delivery and injectable packaging lines. For Apax Partners, the acquisition extends its footprint in industrial and healthcare-adjacent manufacturing, adding a global network of 15 plastic packaging plants to its portfolio. Rival packaging suppliers and contract manufacturers serving the pharmaceutical sector are likely to watch closely, since Centor’s US site and the Primary Packaging Plastics network give Apax immediate scale in prescription drug dispensing packaging, a category with steady, defensive demand tied to pharmaceutical volumes rather than discretionary consumer spending. Notably, the deal comes months after Gerresheimer rebuffed a takeover approach from US rival Silgan in April 2026, according to a Reuters report, underscoring how consolidation pressure has been building across the pharmaceutical packaging space this year.
Market Reaction and Industry Response
Gerresheimer shares moved higher following the announcement, reflecting investor relief that the company is taking concrete steps to address its balance sheet after a loss-making fiscal 2025. Analysts covering the German packaging and pharma-services sector have generally framed the divestment as a credibility-restoring move, since it converts non-core plastics assets into cash that can be redirected toward debt paydown rather than requiring fresh equity. Trade publications covering the packaging sector, including Packaging Gateway and PlasticsToday, described the transaction as one of the largest pharmaceutical packaging divestments of the year. No formal statement has yet been issued by Silgan or other rival bidders regarding the completed Apax deal.
What Happens Next?
The Centor sale is expected to close by the end of Gerresheimer’s fiscal year 2026, while the Primary Packaging Plastics business is projected to complete in the first half of fiscal year 2027, subject to regulatory clearances in the nine countries where the plants operate. Investors will be watching Gerresheimer’s upcoming quarterly results for details on how the proceeds are deployed against its debt load and the terms of the “comprehensive refinancing” CFO Wolf Lehmann referenced. Apax, meanwhile, will need to integrate a geographically dispersed manufacturing network spanning nine countries, a process that typically unfolds over several quarters post-close.
Frequently Asked Questions
How much is Gerresheimer’s packaging sale worth?
The two divested units, Centor and the global Primary Packaging Plastics business, carry a combined enterprise value of €1.5 billion, or approximately $1.7 billion, according to Gerresheimer’s July 29, 2026 announcement.
Who is buying Gerresheimer’s plastic packaging units?
An affiliate of funds advised by private equity firm Apax Partners is acquiring both businesses. Each transaction will close separately, subject to customary regulatory approvals.
Why is Gerresheimer exiting the plastics packaging business?
The company wants to reduce debt and refocus on higher-margin segments such as drug delivery systems, medical devices, and primary packaging for injectable drugs, following a €318.7 million net loss in fiscal 2025.
Leave a comment